| Nov 20 |
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
| Nov 19 |
Immatics Sees Revenue Surge Despite R&D Expenses
|
| Nov 18 |
Immatics GAAP EPS of -€0.11, revenue of €50.56M
|
| Nov 18 |
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
|
| Nov 8 |
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
|
| Oct 23 |
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50%
|
| Oct 12 |
Immatics: A Promising TCR Pipeline
|
| Oct 11 |
Immatics Advances IMA203 to Phase 3 Trial in Melanoma
|
| Oct 11 |
Immatics prices $150M equity offering
|
| Oct 11 |
Immatics Announces Pricing of $150 Million Public Offering
|
